期刊
DRUG DISCOVERY TODAY
卷 23, 期 3, 页码 575-591出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2018.01.037
关键词
-
资金
- National Institutes of Health [CA201402]
- NATIONAL CANCER INSTITUTE [R01CA201402] Funding Source: NIH RePORTER
Tissue transglutaminase (tTG) is capable of binding and hydrolyzing GTP, as well as catalyzing an enzymatic transamidation reaction that crosslinks primary amines to glutamine residues. tTG adopts two vastly different conformations, depending on whether it is functioning as a GTP-binding protein or a crosslinking enzyme. It has been shown to have important roles in several different aspects of cancer progression, making it an attractive target for therapeutic intervention. Here, we highlight many of the major findings involving tTG since its discovery 60 years ago, and describe recent drug discovery efforts that target specific activities or conformations of this unique protein.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据